Loading
Breast Cancer Treatment Studies · Journal article
Journal of Clinical Medicine · September 10, 2026
A consensus or society position rather than new primary data.
This is a narrative review that synthesizes current breast cancer therapeutic recommendations and their relevance to reconstructive planning and perioperative management. It is a clinical summary intended to educate plastic surgeons on oncologic treatment indications and sequencing, not an original evidence assessment or guideline consensus statement.
Narrative review. Patients undergoing breast reconstruction after mastectomy or breast-conserving surgery, informed by tumor characteristics, comorbidities, and systemic therapy anticipation..
Postmastectomy radiation therapy, chemotherapy, immunotherapy, endocrine therapy, and targeted therapies all influence reconstructive timing and complication risk. Strategic timing of reconstruction through individualized planning, informed by systemic therapy knowledge, can improve reconstructive success.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Plastic surgeons should integrate knowledge of contemporary cancer therapies and their perioperative effects into reconstructive decision-making and timing to optimize patient outcomes and safety.
A narrative review summarizing current therapeutic indications and their perioperative implications for reconstructive planning; expert synthesis rather than original evidence.
As stated by the source record.
Plastic surgeons should integrate knowledge of contemporary cancer therapies and their perioperative effects into reconstructive decision-making and timing to optimize patient outcomes and safety.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Breast reconstruction after mastectomy or breast-conserving surgery requires careful planning that accounts for patient preference, comorbidities, tumor characteristics, and anticipated neoadjuvant or adjuvant therapies. Advances in the treatment of breast cancer have led to evolving recommendations for these therapies, with each influencing not just the complications from surgery but also the long-term outcomes. This narrative review summarizes the current indications for these therapies and their potential impacts on breast reconstruction. Contemporary recommendations for postmastectomy radiation therapy, chemotherapy, immunotherapy, endocrine therapy, and other targeted therapies are explored, with an emphasis placed on perioperative management of systemic therapies and how they may influence reconstructive decision-making. Understanding the nuances of these therapies enables plastic surgeons to be strategic in the timing of reconstruction through individualized planning and can improve reconstructive success. As breast cancer treatment evolves, familiarity with oncologic management is essential for achieving safe, patient-centered care.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.